UK markets closed
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • FTSE 250

    22,646.08
    -38.76 (-0.17%)
     
  • AIM

    1,182.30
    -6.44 (-0.54%)
     
  • GBP/EUR

    1.1690
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • BTC-GBP

    36,658.73
    +111.47 (+0.31%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • DOW

    34,580.08
    -59.71 (-0.17%)
     
  • CRUDE OIL

    66.22
    -0.28 (-0.42%)
     
  • GOLD FUTURES

    1,782.10
    +21.40 (+1.22%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,169.98
    -93.13 (-0.61%)
     
  • CAC 40

    6,765.52
    -30.23 (-0.44%)
     

Merck KGaA raises forecast for full year 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Merck KGaA / Key word(s): Change in Forecast/9 Month figures
Merck KGaA raises forecast for full year 2021

03-Nov-2021 / 18:42 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Darmstadt, November 3, 2021. Based on a very strong third quarter of 2021 with net sales of EUR 4.97 bn resulting in EBITDA pre1 of EUR 1.55 bn and EPS pre1 of EUR 2.24, Merck KGaA (the "Company") has further raised its forecast for the entire group for fiscal 2021. The main driver is a very strong operating performance from the Life Science business sector. The Company now projects net sales of approx. EUR 19.30 - 19.85 bn (previously EUR 18.80 - 19.70 bn). EBITDA pre1 is anticipated to grow to approx. EUR 6.0 - 6.3 bn for the group (previously "EUR 5.6 - 6.0 bn"). EPS pre1 is projected to amount to approx. EUR 8.50 - 9.00 (previously "EUR 7.80 - 8.50").
The Company will publish Q3 / 2021 figures as scheduled on 11 November 2021.

1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical shares outstanding (see Merck Annual Report 2020).

Andreas Cezanne, Leiter Corporate Media Relations
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Deutschland
Email: investor.relations@merckgroup.com
Internet: www.merck.de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX

03-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Merck KGaA

Frankfurter Str. 250

64293 Darmstadt

Germany

Phone:

+49 (0)6151 72 - 2702

E-mail:

Andreas.Cezanne@merckgroup.com

Internet:

https://www.merckgroup.com/de

ISIN:

DE0006599905

WKN:

659990

Indices:

DAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX

EQS News ID:

1246001


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting